-
Product Insights
Round Cell Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Round Cell Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Round cell liposarcoma, also called myxoid or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS tumors usually grow in the arms and legs. These tumors grow slowly, and they can spread to other parts of the body. The Round Cell Liposarcoma drugs in development...
-
Product Insights
Acute Lymphoblastic Lymphoma - Drugs In Development, 2024
Empower your strategies with our Acute Lymphoblastic Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Acute lymphoblastic lymphoma (ALL) is a heterogeneous hematologic malignancy involving proliferation of lymphoid progenitor cells (of B cell or T cell lineage) that invades bone marrow, peripheral blood, and extramedullary locations. ALL is a disease with ≥ 20% of lymphoblasts (atypical lymphoid or undifferentiated cells) in bone marrow lymphoblasts or peripheral blood. The Acute Lymphoblastic Lymphoma drugs in development market research...
-
Product Insights
Anaplastic Oligoastrocytoma - Drugs In Development, 2024
Empower your strategies with our Anaplastic Oligoastrocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the...
-
Product Insights
Duodenal Cancer - Drugs In Development, 2024
Empower your strategies with our Duodenal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Duodenal cancer is a type of malignancy that develops in the duodenum, which is a part of the small intestine. A malignancy involves cancerous cells that can metastasize (spread to other sites or invade and destroy nearby tissues). The most common type of duodenal cancer is adenocarcinoma. The Duodenal Cancer drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Peritoneal Tumor - Drugs In Development, 2024
Empower your strategies with our Peritoneal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Peritoneal tumor is the invasion of the serous membrane lining the peritoneal cavity by malignant cells, that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. The malignant cells originate de novo in the mesothelioma or disseminate from other primary tumor sites. The Peritoneal Tumor drugs in development market research report provide comprehensive...
-
Product Insights
Recurrent Malignant Glioma - Drugs In Development, 2024
Empower your strategies with our Recurrent Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent malignant glioma is defined as the recurrence of a glioma tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back,...
-
Product Insights
Secondary Acute Myeloid Leukemia - Drugs In Development, 2024
Empower your strategies with our Secondary Acute Myeloid Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Secondary acute myeloid leukemia includes acute myeloid leukemia that arises either from a previous myeloid hematologic disease such as myelodysplastic syndrome, chronic myeloproliferative syndrome, or myelodysplastic/myeloproliferative overlap syndromes or from a previous chemotherapy or radiotherapy performed for another disease The Secondary Acute Myeloid Leukemia drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary...
-
Product Insights
Acral Lentiginous Melanoma - Drugs In Development, 2024
Empower your strategies with our Acral Lentiginous Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time. The...
-
Product Insights
Cutaneous Angiosarcoma - Drugs In Development, 2024
Empower your strategies with our Cutaneous Angiosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous angiosarcoma (cAS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and suboptimal treatment options. The Cutaneous Angiosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Cutaneous Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report...
-
Product Insights
Ductal Carcinoma In Situ - Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma In Situ – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer. The Ductal Carcinoma In...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.